1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Daito Pharmaceutical Co., Ltd.

Daito Pharmaceutical Co., Ltd.

TTSE:4577
1,335.00
JPY
-5.00
(-0.37%)
29.54BMarket Cap
Jan 08Next Earn
Daito Pharmaceutical Co., Ltd.
TSE:4577
(Tokyo Stock Exchange)

Recent

price

1,335.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
1,163.56
1,252.65
1,300.3
1,304.29
1,265.05
1,319.57
1,379.3
1,448.81
1,494.27
1,605.56
1,621.65
1,419.48
1,568.51
1,494.38
1,664.74
1,721.97
- -
Revenue per Share
45.71
64.09
80.22
75.72
83.42
93.21
96.48
110.5
127.61
140.75
141.36
152.45
125.2
105
62.72
107.47
- -
Basic EPS, GAAP
-10.97
18.77
30.64
17.13
-43.82
-36.31
75.46
57.82
117.16
54.7
-38.85
-11.86
-48.72
-34.86
-39.38
141.43
- -
Free Cash Flow per Basic Share
8.25
8.25
12.02
12.37
17.31
13.61
13.63
14.99
16.37
17.91
21.91
21.55
32.38
28.9
32.81
38.04
- -
Dividend per Share
478.33
531.33
616.57
680.42
779.43
841.12
921.36
1,019.25
1,123.93
1,260.26
1,379.46
1,504.87
1,598.26
1,702.33
1,734.24
1,840.08
1,734.24
Book Value per Share
465.15
509.02
593.23
655.83
760.48
826.59
909.67
1,007.26
1,112.8
1,249.92
1,368.46
1,492.59
1,586.37
1,686.31
1,716.53
1,780.52
1,716.53
Tangible Book Value per Share
22
22
22
24
27
28
28
28
28
28
30
31
29
31
30
29
31
Basic Weighted Avg Shares
25,218
27,149
28,959
31,202
34,062
36,331
37,973
39,884
41,135
44,997
48,709
43,464
45,101
46,895
50,643
50,650
- -
Sales/Revenue/Turnover
7.77
9.67
9.25
9.42
10.33
9.79
10.09
10.43
11.05
11.91
12.13
15.08
11.55
8.3
5.17
7.18
- -
Operating Margin (%)
2,093
2,271
2,569
2,445
2,440
2,643
2,818
2,853
2,853
2,950
3,154
3,313
3,870
3,659
4,332
4,387
- -
Depreciation Expense
991
1,389
1,787
1,811
2,246
2,566
2,656
3,042
3,513
3,945
4,246
4,668
3,600
3,295
1,908
3,161
- -
Net Income, GAAP
40.97
43.41
31.51
37.11
33.69
25.65
32.38
29.34
24.3
29.85
29.22
31.13
30.52
24.66
40.3
22.83
- -
Effective Tax Rate (%)
3.93
5.12
6.17
5.81
6.59
7.06
7
7.63
8.54
8.77
8.72
10.74
7.98
7.03
3.77
6.24
- -
Profit Margin (%)
2,010
1,971
4,907
5,194
5,731
7,015
9,111
11,373
12,743
15,801
19,571
23,840
25,235
22,955
24,659
22,631
24,659
Working Capital
6,016
5,547
5,346
4,475
3,492
3,692
3,712
4,028
3,098
1,583
2,018
2,247
3,445
6,345
8,428
5,973
8,428
LT Debt
10,368
11,517
15,074
16,625
21,855
23,560
25,814
28,496
31,349
36,868
41,916
47,671
50,971
52,264
52,067
52,937
52,067
Total Equity
5.1
6.19
6.7
6.11
7.11
7.46
7.13
7.97
9.25
9.56
9.51
9.12
6.64
4.99
2.49
4.41
- -
Return on Invested Capital (%)
4.93
6.31
6.96
6.29
7.16
7.5
7.59
8.58
9.67
10.32
10.15
9.78
6.88
5.89
3.4
5.21
- -
Return on Capital (%)
9.9
12.7
13.6
11.68
11.9
11.5
10.95
11.39
11.91
11.7
10.87
10.5
7.35
6.41
3.67
6.03
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Aug'25
Nov'25
May'25
ST Debt
- -
3,299
3,457
LT Borrowings
- -
8,019
6,569
LT Finance Leases
- -
- -
1,859
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
31
31
30
Market Capitalization
36,321
32,131
29,536

Working Capital

JPY

•

in mil. unless spec.
Aug'25
Nov'25
May'25
Total Current Assets
- -
43,601
41,708
Cash, Cash Equivalents & STI
- -
3,241
2,207
Accounts Receivable, Net
- -
11,689
12,669
Inventories
- -
21,069
18,412
Total Current Liabilities
- -
17,437
17,049
Payables & Accruals
- -
- -
- -
ST Debt
- -
3,299
3,457
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.57%
4.9%
1.67%
Free Cash Flow
-69.97%
-48.52%
-447.25%
Net Income, GAAP
5.56%
0.43%
65.67%
Sales/Revenue/Turnover
3.53%
1%
0.01%
Total Cash Common Dividend
12.28%
12.19%
12.12%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12,178
11,932
10,552
12,233
46,895
2025
- -
- -
- -
- -
50,643
2026
- -
- -
- -
- -
50,650

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
21.61
27.49
25.07
30.82
105
2025
- -
- -
- -
- -
62.72
2026
- -
- -
- -
- -
107.47

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
28.9
2025
- -
- -
- -
- -
32.81
2026
- -
- -
- -
- -
38.04
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Daito Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products with a focus on active pharmaceutical ingredients (APIs) for generic drugs, generic drug development and manufacturing, over-the-counter (OTC) drugs, and contract manufacturing services. The company offers a comprehensive range of pharmaceutical-related products including solid dosage forms and packaging solutions and serves major and mid-sized generic drug manufacturers as well as new drug developers. Headquartered in Toyama, Japan, and founded in 1965, Daito operates extensive manufacturing facilities capable of high-mix, low-volume production to meet diverse client needs across Japan. Recently, the company executed an absorption-type merger with its wholly owned subsidiary Daiwa Pharmaceutical Co., Ltd. effective June 2025 to streamline operations and improve manufacturing quality and efficiency. Additionally, Daito announced a strategic collaboration dialogue with Meiji Seika Pharma to establish a consortium aimed at integrating generic pharmaceutical manufacturers, promoting industry realignment. The company has also been active in share repurchases during 2025, reflecting its commitment to shareholder value. These initiatives complement its ongoing pharmaceutical manufacturing, regulatory service expertise, and stable supply capabilities aligned with increasingly stringent quality standards and governmental healthcare policies in Japan.